Fig. 1
From: Cas13b-mediated RNA targeted therapy alleviates genetic dilated cardiomyopathy in mice
A hTNNT2R141W transgenic mouse model with DCM. (A) Schematic showing the procedure for constructing hTNNT2R141W transgenic mice (R141W mice). (B) DNA gel electrophoresis of PCR-amplified DNA products extracted from mouse tails. The 369 bp PCR products were present in lanes 3, 6 and 8. Lane 1, H2O; lane 2, negative control; line 3, positive control; lane 4, DNA molecular weight marker (DL2000); lane 5, WT mouse; lane 6, R141W-1 (hTNNT2R141W transgenic mice); lane 7, WT mouse; and line 8, R141W-2. (C) Undigested and digested TNNT2 PCR products for WT control (lanes 2 and 4) and R141W mice (lanes 3 and 5). (D) qRT-PCR analysis of mRNA levels of hTNNT2R141W transgene in the heart, liver, spleen, lung and brain. (E) Histopathological profile of heart tissue from mice at 4 months of age. H&E staining patterns of whole-heart longitudinal sections are shown. Scale bars = 500 μm. (F) Echocardiographic analyses of mouse hearts. Four-month-old WT mice (n = 30) and R141W mice (n = 23) were analyzed by M-mode echocardiography. The transgenic heart showed an enlarged ventricular chamber and decreased movement of the ventricular wall. EF, left ventricular ejection fraction. FS, left ventricular fractional shortening. LVID; d, diastolic left ventricular internal diameter. LVID;s, systolic left ventricular internal diameter. IVS;s, systolic interventricular septum. The bar graphs show the mean ± SEM. ***p < 0.001 according to Student’s t test [53,54,34]